Journal of veterinary science · 2026
Primer-walking sequencing identifies predominantly noncoding TP53 variants in canine cancers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mathiyalagan Ramya, Lee Chanjoong, Jo Yongsuk, Lee Jaebeom, Song Joong-Hyun
Аннотация
IMPORTANCE: Tumor protein p53 (TP53) alterations are frequently reported in canine cancers but remain incompletely characterized due to differences in reference genomes and sequencing cost.
OBJECTIVE: To evaluate a cost-efficient primer-walking approach for TP53 variant screening in dogs with spontaneous tumors.
METHODS: Tumor tissue (n = 10) or blood (n = 16) was collected from 26 dogs with suspected neoplasia. Interpretable TP53 sequences spanning introns and exons 2-11, excluding long intron 1 and non-protein-coding exon 1, were obtained by primer-walking polymerase chain reaction and Sanger sequencing. Bidirectional reads were compared with the Ensembl ROS_Cfam_1.0 v114 reference sequence.
RESULTS: TP53 gene sequence variations were observed in 18/26 sequenced tumor cases, including one exonic frameshift insertion and 17 noncoding variants: 13 intronic variants and 4 variants in the 5' untranslated region. Recurrent substitutions and deletions occurred in the intron 8-10 region. Variants were detected in lymphomas and carcinomas, including cases from several small breeds, but no significant association with tumor type or breed was demonstrated.
CONCLUSIONS AND RELEVANCE: Primer-walking Sanger sequencing can screen TP53 regions beyond coding exons in canine tumor samples. Matched tumor-normal sequencing is needed to determine somatic versus germline origin and to evaluate noncoding TP53 variants as potential biomarkers or drivers.
OBJECTIVE: To evaluate a cost-efficient primer-walking approach for TP53 variant screening in dogs with spontaneous tumors.
METHODS: Tumor tissue (n = 10) or blood (n = 16) was collected from 26 dogs with suspected neoplasia. Interpretable TP53 sequences spanning introns and exons 2-11, excluding long intron 1 and non-protein-coding exon 1, were obtained by primer-walking polymerase chain reaction and Sanger sequencing. Bidirectional reads were compared with the Ensembl ROS_Cfam_1.0 v114 reference sequence.
RESULTS: TP53 gene sequence variations were observed in 18/26 sequenced tumor cases, including one exonic frameshift insertion and 17 noncoding variants: 13 intronic variants and 4 variants in the 5' untranslated region. Recurrent substitutions and deletions occurred in the intron 8-10 region. Variants were detected in lymphomas and carcinomas, including cases from several small breeds, but no significant association with tumor type or breed was demonstrated.
CONCLUSIONS AND RELEVANCE: Primer-walking Sanger sequencing can screen TP53 regions beyond coding exons in canine tumor samples. Matched tumor-normal sequencing is needed to determine somatic versus germline origin and to evaluate noncoding TP53 variants as potential biomarkers or drivers.